Edition:
United States

Biotechnology & Medical Research

Page 1

Kalobios to have FDA meeting for using benznidazole to treat Chagas disease

Monday, 5 Dec 2016 07:30am EST

Kalobios Pharmaceuticals Inc : Kalobios Pharmaceuticals Inc - "expect to have an FDA meeting to confirm regulatory pathway for benznidazole in treatment of Chagas disease" . Kalobios Pharmaceuticals Inc - to continue enrolling patients in company's ongoing phase 1 study of lenzilumab for chronic myelomonocytic leukemia . Kalobios Pharmaceuticals Inc - to explore partnering other proprietary monoclonal antibodies (MABS), such as ifabotuzumab .Says work on benznidazole program has accelerated since co acquired rights in June 2016.

Basilea Pharmaceutica: expansion of BAL101553 clinical phase 1/2a oral formulation study

Friday, 2 Dec 2016 01:15am EST

Basilea Pharmaceutica AG :Expands oncology drug candidate BAl101553 clinical phase 1/2a oral study to include glioblastoma patients.

Neuron Bio receives patent in Mexico for its NST0037 neuroprotective compound

Friday, 25 Nov 2016 02:08am EST

Neuron Bio SA :Says receives patent in Mexico for its NST0037 compound for neurodegenerative diseases.

Anhui Anke Biotechnology Group sets up med lab in Hefei city

Friday, 11 Nov 2016 03:59am EST

Anhui Anke Biotechnology Group Co Ltd <300009.SZ> :Says it sets up a med lab as wholly-owned subsidiary in Hefei city with investment of 23 million yuan.

iNtRON Biotechnology receives patent

Thursday, 10 Nov 2016 08:54pm EST

iNtRON Biotechnology Inc <048530.KQ> : Says it received patent on Nov. 10, for novel lactococcus garvieae bacteriophage lac-gap-1 and its use for preventing proliferation of lactococcus garvieae .Patent application number is 10-2015-0008012.

BRIEF-Targovax granted European patent for ONCOS-102

Thursday, 10 Nov 2016 01:00am EST

Targovax ASA : Has been granted European patent for oncos platform lead product, Oncos-102 .Composition of matter patent protects Targovax's lead product from its oncos platform, oncolytic viral product oncos-102 and expires in 2029.

Biocon and Mylan announce U.S. FDA submission for proposed biosimilar Trastuzumab

Tuesday, 8 Nov 2016 06:59am EST

Biocon Ltd :Biocon Ltd says Mylan and Biocon announce U.S. FDA submission for proposed biosimilar trastuzumab.

ilShinBiobase receives patent

Sunday, 6 Nov 2016 09:51pm EST

ilShinBiobase Co Ltd <068330.KQ> :Says it received patent on Nov. 4, for freeze dryer(containing loading and unloading system which can automatically supply or produce pharmaceutical vial and materials).

Factor Therapeutics receives FDA notice of removal of clinical hold

Sunday, 6 Nov 2016 04:52pm EST

Factor Therapeutics Ltd : Received a notice of removal of full clinical hold from U.S. Food And Drug Administration .Is now permitted to proceed with its clinical trial.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary